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Morphological alterations of mitochondria may play an important role in the pathogenesis of Alzheimer’s disease, been associated
with oxidative stress and Aβ-peptide-induced toxicity. We proceeded to estimation of mitochondria on electron micrographs of
autopsyspecimensofAlzheimer’sdisease.Wefoundsubstantialmorphologicalandmorphometricchangesofthemitochondriain
the neurons of the hippocampus, the neocortex, the cerebellar cortex, the thalamus, the globus pallidus, the red nucleus, the locus
coeruleus, and the climbing ﬁbers. The alterations consisted of considerable changes of the cristae, accumulation of osmiophilic
material, and modiﬁcation of the shape and size. Mitochondrial alterations were prominent in neurons, which showed a depletion
of dendritic spines and loss of dendritic branches. Mitochondrial alterations are not related with the accumulation of amyloid
deposits, but are prominent whenever fragmentation of the Golgi apparatus exists. Morphometric analysis showed also that
mitochondria are signiﬁcantly reduced in neurons, which demonstrated synaptic pathology.
1.Introduction
Alzheimer’s disease (AD) is an insidiously progressive severe
presenile and senile dementia, involving a number of cellular
and biochemical mechanisms, aﬀecting millions of humans
as the most common cause of cognitive decline worldwide.
From the clinical point of view AD is mostly character-
ized by age-dependent cognitive decline aﬀecting memory
primarily, associated frequently with behavioral and mood
disorders, which increasingly appear as the disease advances
[1].
From the neuropathological point of view, Alzheimer’s
disease is mostly characterized by selective neuronal loss [2,
3], marked synaptic alterations [4–6], morphological mito-
chondrial abnormalities [7, 8], tau pathology [9] resulting
in neuroﬁbrillary degeneration (NFT) [10], inﬂammatory
responses and mainly by extracellular extensive deposits of
polymers of Aβ peptide in the form of neuritic plaques
[11, 12] in the neocortex, the hippocampus, and many sub-
cortical structures, which are involved in cognitive function.
The production and accumulation of Aβ peptide are the
result of the posttranslational proteolysis of the APP [13],
which is one of the deﬁning features, as real pathological
hallmark, for the neuropathological diagnosis of the dis-
ease. In addition Alzheimer’s disease is characterized ultra-
structurally by organelle pathology involving mostly the mi-
crotubules, the mitochondria, and Golgi apparatus [14].
From the etiological point of view it would be hypoth-
esized that the multiple genetic loci [15, 16], associated
with familial Alzheimer’s disease would plead in favor of
the heterogeneity of the disease and support the idea that
the phenomenological expression of Alzheimer’s disease is
the ﬁnal consequence of various metabolic, neurochemical,
and morphological alterations, based on a broad genetic
background [17], since accumulation of Aβ peptide at
synaptic terminals may be associated with synaptic damage
and cognitive decline in patients with AD [18].
Although the majority of familial or inherited AD, which
manifests at an early age, are often associated with mutations
in AβPP [19], the vast majority of the sporadic ones, which
manifests usually at later stages of life, are proved to be
multifactorial, including induced expression of AβPP [20–
22] by pathological stimuli, environmental factors, as well as
deprivation of trophic factors.2 International Journal of Alzheimer’s Disease
Moreover the increased risk of Alzheimer’s disease in
sporadic cases, when a maternal relative is aﬄicted with the
disease pleads on the other hand in favor of a maternally
derived predisposition, was related probably to mitochon-
drialDNA(mtDNA)[23].Mitochondrialdysfunctiononthe
other hand is associated with oxidative stress, which may
play an important role in the early pathogenetic stages of
Alzheimer’sdisease[24,25],presumablypriortotheonsetof
thecognitivedysfunctionsinceasubstantialbodyofevidence
suggests that mitochondria play a crucial role in ageing-
related neurodegenerative diseases [24].
2.MaterialandMethods
2.1. Patients. We studied the hippocampus, the acoustic cor-
tex, the visual cortex, the thalamus, the globus pallidus, the
locus coeruleus, the red nucleus, and many areas of the
cerebellar cortex in ten brains of patients who suﬀered from
Alzheimer’s disease, four men and six women, aged 62–87
years, who fulﬁlled the clinical, neuropsychological, and lab-
oratory diagnostic criteria of Alzheimer’s disease. The mean
education of the patients was 15.2 years, and all of them
spoke their native language ﬂuently. Screening procedures
were applied included medical history, medical examination,
cardiological investigation, and physical neurologic assess-
ment, and psychiatric and neuropsychological examinations.
All the patients underwent EEG, carotid duplex Doppler,
computerized tomography (CT) scanning and magnetic res-
onance imaging (MRI)of the brain, and single-photon emis-
sion computed tomography (SPECT).
The mental status of the patients was assessed by Min-
imental State Examination (MMSE) and dementia rating
scale (DRS) [26] and ADAS-COX test.
The cause of death of the patients was heart arrest fol-
lowing to cardiac infarct one to seven months after the ﬁnal
neurological assessment.
The postmortem examination of each one of the cases
was performed within 6h after death.
2.2. Electron Microscopy. Small samples from the hippocam-
pus (2 × 2 × 2mm), the acoustic cortex, the visual cortex,
the thalamus, the globus pallidus, the locus coeruleus, and
from many areas of the cerebellar cortex were excised
and immersed in Sotelo’s ﬁxing solution, composed of 1%
paraformaldehyde, 2.5% glutaraldehyde in cacodylate buﬀer
0.1M, adjusted at pH 7.35. Then they were postﬁxed by
immersion in 1% osmium tetroxide for 30min at room tem-
perature and dehydrated in graded alcohol solutions and
propylene oxide.
Thin sections were cut in a Reichert ultratome, con-
trasted with uranyl acetate and lead citrate, and studied in a
Zeiss 9aS electron microscope.
Wealsostudiedthemorphologyofthemitochondria,the
Golgiapparatus,andthesynapsesandproceededtomorpho-
metricestimationsatelectronmicroscopeonmicrographsof
a standard magniﬁcation of 56.000x.
2.3. Light Microscope, Golgi Staining, Golgi-Nissl Method.
The remaining parts of the above-mentioned areas of the
brain and the cerebellum were processed for silver impreg-
nation techniques, according to rapid Golgi staining. Thus,
after a four-week ﬁxation in formalin they were immersed in
potassium dichromate (7g potassium dichromate in 300mL
water) for 10 days. Then they were immersed in 1% silver
nitrate for 10 days. Following a rapid dehydration in graded
alcohol solutions, the specimens were embedded in paraﬃn
and cut, some of them at 100μ and some at 25μ,a l t e r n a -
tively.
The sections of 25μ were stained also with methylene
blue, according to Golgi-Nissl method. All the sections were
mounted in permount, between two cover slips and studied
in a Zeiss Axiolab Photomicroscope.
We estimated the dendritic arborization, the number of
the branches, and the dendritic spines morphometrically in
light microscope in sections stained according to rapid Golgi
method and Golgi-Nissl staining.
2.4. Statistical Analysis. Statistical analysis was based on the
t-test on the basis of 5000 mitochondria from 30 specimens
of Alzheimer’s disease brains and 30 specimens of normal
control brains.
3. Results
3.1. Silver Impregnation Technique. Application of the silver
impregnation technique revealed neuronal loss and marked
abbreviation of the dendritic arborization in all the layers
of the acoustic and the visual cortex, the hippocampus, the
thalamus, the globus pallidus, the locus coeruleus, the red
nucleus, and the cerebellar cortex. Layer I, of the acoustic
and visual cortex, which includes Cajal-Retzius cells, which
normally develop very long horizontal axonic proﬁles [27,
28], was practically empty of neurons in the patients who
suﬀered from Alzheimer’s disease, in contrast to normal
control brains. Loss of tertiary dendritic branches was also
noticed in the acoustic and the visual cortex in all of the
specimens.
Abbreviation of the dendritic arborization was promi-
nent mostly in the neurons of layers III and V of the acoustic
and visual cortex, in the pyramidal neurons of the hip-
pocampus as well as in the polyhedral neurons of the locus
coeruleus and the Purkinje cells of the cerebellar cortex,
which demonstrated also a marked decrease of the number
of dendritic spines in comparison with the normal control
brains.
The axonic collaterals in layers III, IV, V, and VI of the
acoustic and visual cortex were dramatically decreased in
comparison with the normal controls.
Decrease of the branches of the apical dendrites of
the cortical neurons as well as decrease in spine density
was widespread phenomena seen in the large majority of
the neurons of the acoustic and the visual cortex, in the
hippocampus, the thalamus, the globus pallidus, the red
nucleus, the locus coeruleus, and the cerebellar neurons.International Journal of Alzheimer’s Disease 3
Figure 1:DendriticproﬁleofaPurkinjecellinacaseofAlzheimer’s
disease including elongated mitochondrion, showing disruption of
the cristae. The presynaptic proﬁle, presumably a terminal of par-
allel ﬁber is characterized by the marked poverty of the synaptic
vesicles (mag. 65.000x).
3.2. Electron Microscopy. Electron microscopy revealed path-
ological alterations of the dendritic spines and impressive
decrease in spine density in the secondary and tertiary den-
dritic branches in all the layers of the acoustic and visual
cortex.
Reduction in spine size was prominent in neurons of
layers II, III, and V. A substantial number of dendritic spines
demonstrated large multivesicular bodies, dysmorphic spine
apparatus, and mitochondria, which were characterized by
marked morphological alterations.
Morphological alterations of the dendritic spines were
noticed also in the pyramidal neurons of the hippocampus,
the large polyhedral neurons of the thalamus and the globus
pallidus, the polyhedral neurons of the locus coeruleus as
well as the Purkinje cells of the cerebellar hemispheres. Giant
spines were seen mostly in the hippocampus and in the
Purkinje cells of the cerebellum.
In large number of presynaptic terminals in the acoustic
and the visual cortex of the patients who suﬀered from
Alzheimer’s disease, the ultrastructural study revealed an
impressivepolymorphismandpleomorphismofthesynaptic
vesicles, which were dramatically decreased in number in
comparison with normal control brains (Figure 1).
Impressive poverty of the synaptic vesicles was particu-
larly seen in the presynaptic terminals in layers III, IV, and V
of the acoustic and visual cortex as well as in the mossy ﬁbers
of the cerebellar cortex (Figure 2). Decrease of the number of
synaptic vesicles and marked polymorphism of the remained
vesicles was also seen in the hippocampus the thalamus, the
locus coeruleus, and in the parallel and climbing ﬁbers of the
cerebellar cortex.
Mitochondrial pathology was seen in the majority of the
dendritic spines in all of the specimens, which consisted
of substantial change of shape and size, fragmentation
of cristae, and accumulation of osmiophilic material in a
considerable number of mitochondria.
Figure 2: Mossy ﬁbers of the cerebellar cortex in a case of Alz-
heimer’s disease showing decrease of the number of the synaptic
vesicles and lack of mitochondria (mag. 65.000x).
Figure 3: Small dense mitochondrion associated with fragmenta-
tion of the cisternae of Golgi apparatus (meg. 70.000x).
Many dendritic proﬁles contained mitochondria, which
showed an impressive polymorphism in the arrangement of
the cristae, which sometimes showed a concentric conﬁgura-
tion or in other places they were arranged in a parallel way
to the long axis of the organelle. Some dendrites of Purkinje
cells and a substantial number of climbing ﬁbres contained
very large elongated mitochondria.
Small round mitochondria intermixed with dense bodies
or associated with fragmentation of the Golgi apparatus
(Figure 3) were seen in the soma of a considerable number
of neurons of the visual cortex, the hippocampus, the locus
coeruleus, the red nucleus, the large polyhedral neurons
of globus pallidus, and the Purkinje cells of the cerebellar
cortex in contrast to normal control brains, in which the
mitochondria looked unremarkable.
Itisworthtoemphasizethatmorphologicalalterationsof
themitochondriawerealsoseeninthesoma,theperivascular
astrocyticprocesses,andtheastrocyticsheathsinAlzheimer’s
brains in contrast to normal controls.
From the morphometric point of view the ellipsoid
mitochondria in the dendritic spines of the normal control
brains appear to have an average diameter of 650 ± 250nm4 International Journal of Alzheimer’s Disease
and a mean axial ratio of 1.9 ± 0.2. The round or global
mitochondria in normal controls appeared as having a mean
mitochondrial radius of 350nm.
In Alzheimer’s disease brains, the ellipsoid mitochondria
of the neurons of the acoustic and the visual cortex appear
to have an average diameter of 480 ± 250nm and a mean
axialratioof1.7 ±0.2.Theroundmitochondriahaveamean
radius of 280nm.
4. Discussion
The mitochondria, which are the only nonnuclear con-
stituents of the cell with their own DNA (mtDNA), having
machinery for synthesizing RNA and proteins, are critical
to homeostasis of the cell, by virtue of providing most of
the energy for cellular processes and by their involvement
in other metabolic pathways. Mitochondria are also critical
regulators of cell apoptosis, as being involved in a con-
siderable number of neurodegenerative diseases [29, 30],
since it is well known that energy production, realized
by oxidative phosphorylation, occurs in the mitochondria,
which generate most of the cell’s supply of ATP.
From the morphological point of view the shape and
size of the mitochondria as well are highly variable [31], de-
pending on ﬁssion and fusion [32]. Their morphology is
sometimes controlled by cytoskeletal elements, namely the
neuroﬁlaments and the microtubules [33]. The change of the
shapeof themitochondria occursmostly throughtheir move
to axons, dendrites, and synaptic terminals via anterograde
transport [34].
During the various neuronal processes approximately
one-third of the mitochondria are in motion along micro-
tubules and actin ﬁlaments [35–37], whereas the majority of
them are stationary. Mitochondrial motility and accumula-
tion are coordinated, since mitochondria are transported to
regions where ATP consumption and necessity for energy are
particularly high, as it takes place in the synapses, which have
high energy demand for serving neuronal communication
[38].
Mitochondrial alterations and dysfunction have been re-
ported in several neurodegenerative diseases [39–41] associ-
ated mostly with oxidative damage [42] and vascular lesions
[43]. Oxidative stress is mostly associated with amyloid β
(Aβ) accumulation in the neocortex [7, 44, 45], playing
therefore an important role in the pathogenetic mechanisms
of Alzheimer’s disease [46], since it is not only involved
in damage to the proteins of NFT [36] and the formation
of senile plaques but also involves extensive damage to
the cytoplasm of neuronal populations vulnerable to death
during AD [47].
It is also well documented that Aβ peptide may increase
mitochondrial reactive oxygen species (ROS) production
[48], causing further impairment of mitochondrial function
[49] since the lack of histones in mitochondrial DNA renders
them a vulnerable target to oxidative stress.
In all major examples of these diseases there is strong
evidence that mitochondrial dysfunction occurs early and
acts causally in disease pathogenesis. Mutations in mito-
chondrial DNA and oxidative stress, on the other hand, may
contributetoageing,whichisthesubstantialbiologicalback-
ground for the majority of the neurodegenerative diseases
[50]. Mitochondrial dysfunction has been associated with
energy crisis of the cell and excitotoxic cell death and is
considered to be of substantial importance in the cascade of
phenomena, which eventually lead to apoptosis.
Some observations in early cases of Alzheimer’s disease
[51] indicate that morphological alterations of the mito-
chondria and oxidative damage may be one of the earliest
events in Alzheimer’s disease. The morphological alteration
of the mitochondria seen in subcortical centres, such as
in the thalamus, the globus pallidus, the red nucleus, and
the locus caeruleus, pleads in favor of a generalized mito-
chondrial dysfunction in Alzheimer’s disease, which may be
associated with wide neuronal loss and synaptic alterations,
seriously aﬀecting consequently, the mental faculties, which
are basically related to extensive neural networks [52].
Moreover, an impressive number of disease-speciﬁc proteins
interact with mitochondria. Well-documented studies [53]
demonstrate that a signiﬁcant amount of the N-terminal
domain of APP targeted the mitochondria of cortical neu-
ronal cells and select regions of the brain of a transgenic
mouse model for AD. The accumulation of transmembrane-
arrested APP blocked protein translocation, disrupted mito-
chondrial function, and impaired brain energy metabolism.
In Alzheimer’s disease the amyloid precursor protein has
been localized to mitochondria as has the toxic amyloid
beta peptide. The binding site for amyloid beta has been
identiﬁed as alcohol dehydrogenase in the matrix space
of the organelle. Many morphological alterations of AD
could very well be linked to mitochondria changes since
blockage of mitochondrial energy production shifts amyloid
protein precursor metabolism to the production of more
amyloidogenic forms of amyloid [54]. In addition amyloid
beta peptide promotes permeability transition pore in brain
mitochondria [55, 56].
It is important to mention that many protein systems
are also essential in mitochondrial function, their mor-
phological integrity and in binding to the cytoskeleton
[57]. Mitochondrial porin is an outer-membrane protein
that forms regulated channels (Voltage-Dependent Anionic
Channels) between the mitochondrial intermembrane space
and the cytosol. Porin may play an important role in binding
to neuroﬁlaments and microtubules [37], since porin-rich
domains contain most of the binding sites for MAP2 [58].
In addition preselinin-2 modulates endoplasmic reticulum-
mitochondrial interactions [59], a fact that pleads in favour
of the crucialrole that mitochondria play in the pathogenetic
cascade of Alzheimer’s disease.
The number of the mitochondria varies, according to
energy state of the cell. Some evidence suggests that the
mitochondria redistribute towards the dendritic proﬁles in
response to stimulation as a manifestation of synaptic plas-
ticity [60]. Normally a limited number of dendritic spines
contain mitochondria, which are mostly small and round,
been increased in number inside the dendritic branches
during the synaptogenesis. A decrease in energy metabolismInternational Journal of Alzheimer’s Disease 5
and altered cytochrome c oxidase (CytOX) activity are
among the earliest detectable defects in AD [61, 62], af-
fecting presumably neuronal plasticity and synaptogenesis.
Some observations suggest that mitochondrial cytochrome c
oxidase may be inhibited by a dimeric conformer of Aβ35, a
phenomenonwhichemphasizestheroleoftheAβpeptideon
the mitochondrial dysfunction in Alzheimer’s disease [63].
Therapies targeting basic mitochondrial processes, such
as energy metabolism or free-radical generation, or speciﬁc
interactions of disease-related proteins with mitochondria,
hold great promise. On the basis of the mitochondrial pa-
thology,inthepathogeneticspectruminAlzheimer’sdisease,
new strategies inducing protection to mitochondria by the
administrationofeﬃcientantioxidantfactorscouldbeintro-
duced in the treatment of early cases of Alzheimer’s disease.
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